ArticleThrombosis journal2025
A simple formula for predicting the warfarin dose in atrial fibrillation: development, external validation, and model comparison.
Article in Thrombosis journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe dose of warfarin varies between individuals. Several formulas for predicting the maintenance dose of warfarin have been developed; however, most are complicated and not practical for clinical use.
objectiveTo determine factors that predict warfarin dosage and the relationship between clinical variables and the maintenance dose of warfarin, and to develop a simple formula for predicting the maintenance dose of warfarin that is particularly useful for identifying patients with atrial fibrillation (AF) who are at higher risk of bleeding, without relying on pharmacogenetic data. MATERIALS AND
methodsThis was a retrospective cohort study carried out between 2011 and 2021. All patients are started on warfarin with a target INR of 2.0 to 3.0. The prediction models for the maintenance dose were developed using a first-order equation. Correlation and performance of the formula were examined in training and validation cohorts.
resultsA training cohort consisted of 520 patients with a mean age of 69 ± 12 years. The proposed warfarin dosing formula was 3+(0.02×body weight (kg))-(0.02×age (years))-(0.4×serum creatinine (mg/dL)).When compared with a warfarin dosing formula, a 3-mg dose was associated with overdosing with an odds ratio [OR] of 3.31 (95%CI 2.26-4.84, p < 0.0001) in patients whose body weight was < 60 kg, OR 3.08 (95%CI 2.15-4.40, p < 0.0001) in patients aged ≥ 70 years and OR 2.39 (95% CI 1.67-3.44, p < 0.0001) in patients with eGFR < 50 mL/min. The findings in the validation cohort of 632 patients were concordant with the training cohort.
conclusionA simple warfarin dosing formula incorporating age, body weight, and serum creatinine reduced the risk of warfarin overdose in a high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.